New staph vaccine shows promise in early human trial
NCT ID NCT06719219
First seen Oct 31, 2025 · Last updated Apr 25, 2026 · Updated 23 times
Summary
This early-stage study tested a new vaccine called LTB-SA7 in 129 healthy adults to see if it is safe and triggers an immune response against Staphylococcus aureus (staph) bacteria. The vaccine contains seven inactivated toxins to help the body build defenses. Results will help determine the best dose for future studies.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STAPHYLOCOCCUS (S.) AUREUS INFECTION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Naval Medical Research Command Clinical Trial Center
Bethesda, Maryland, 20889, United States
Conditions
Explore the condition pages connected to this study.